Pyrophosphoric Acid

Pyrophosphoric Acid

SCHEMBL3232913

C/C=C(\C)CCC.O=P(O)(O)OP(=O)(O)O

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.43
BLM P54132 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
FNTA P49354 8/20 0.41
FNTB P49356 6/20 0.41
BTN3A1 O00481 4/20 0.39
PGGT1B P53609 3/20 0.38
LPAR3 Q9UBY5 4/20 0.33
LPAR1 Q92633 2/20 0.33
LPAR2 Q9HBW0 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyrophosphoric Acid SCHEMBL3232915 1.00 FDPS (0.43) FDPSBLMTDP1FNTAFNTB
SCHEMBL1760745 0.78
SCHEMBL107786 0.78
SCHEMBL107787 0.78
Pyrophosphoric Acid SCHEMBL30825656 0.77 BTN3A1 (0.55) FDPSBLMTDP1FNTAFNTB
Pyrophosphoric Acid SCHEMBL8761218 0.75 FDPS (0.67) FDPSBLMTDP1BTN3A1LPAR3
SCHEMBL27550641 0.74 FNTA (0.35) FNTAFNTBBTN3A1PGGT1BLPAR3
Acetic Acid SCHEMBL28126454 0.74 FFAR3 (0.48) TDP1
Pyrophosphoric Acid SCHEMBL31372362 0.73 FDPS (0.62) FDPSBLMTDP1BTN3A1LPAR3
Pyrophosphoric Acid SCHEMBL2426695 0.72 FDPS (0.71) FDPSBLMTDP1BTN3A1LPAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100068179-A1 Phosphohalohydrins, Process For The Production Thereof And Use Thereof INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2010-03-18 US disclosed
US-7625879-B2 Phosphohalohydrins, process for the production thereof and use thereof INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2009-12-01 US disclosed
US-7432253-B2 Phosphoepoxides, method for making same and uses INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2008-10-07 US disclosed
US-20060287274-A1 Phosphoepoxides, method for making same and uses INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2006-12-21 US disclosed
US-20060287281-A1 Phosphohalohydrins, process for the production thereof and use thereof INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2006-12-21 US disclosed
US-7109183-B2 Phosphohalohydrins, process for the production thereof and use thereof Institut National de la Sante et de la Recherchik Medicale (FR) 2006-09-19 US disclosed
US-7101711-B1 Phosphoepoxides, method for making same and uses INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE (FR) 2006-09-05 US disclosed
US-20040087555-A1 Phosphohalohydrins, process for the production thereof and use thereof INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICATE (FR) 2004-05-06 US disclosed
US-6660723-B1 Activating primate gamma delta lymphocytes INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2003-12-09 US disclosed
EP-1109818-B1 PHOSPHOEPOXIDES, METHOD FOR MAKING SAME AND USES INST NAT SANTE RECH MED (FR) 2002-11-06 EP disclosed
EP-1109817-B1 PHOSPHOHALOHYDRINS, METHOD FOR MAKING SAME AND USES INST NAT SANTE RECH MED (FR) 2002-06-05 EP disclosed
EP-1109817-A1 PHOSPHOHALOHYDRINS, METHOD FOR MAKING SAME AND USES INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2001-06-27 EP disclosed
EP-1109818-A1 PHOSPHOEPOXIDES, METHOD FOR MAKING SAME AND USES INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2001-06-27 EP disclosed
WO-2000012516-A1 PHOSPHOHALOHYDRINS, METHOD FOR MAKING SAME AND USES INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2000-03-09 WO disclosed
WO-2000012519-A1 PHOSPHOEPOXIDES, METHOD FOR MAKING SAME AND USES INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2000-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287274-A1 Phosphoepoxides, method for making same and uses CD4, CCR9, BCL9 FDPS 3962/4885BLM 4342/4885TDP1 1768/4885
US-20040087555-A1 Phosphohalohydrins, process for the production thereof and use thereof CD4, HRH3, HRH1 FDPS 4591/4885BLM 2273/4885TDP1 1064/4885
US-20060287281-A1 Phosphohalohydrins, process for the production thereof and use thereof CD4, CCR9, BCL9 FDPS 4491/4885BLM 4010/4885TDP1 2256/4885
US-20100068179-A1 Phosphohalohydrins, Process For The Production Thereof And Use Thereof CD4, CCR9, ICOS FDPS 4659/4885BLM 4374/4885TDP1 2882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.